{
    "nctId": "NCT05203458",
    "briefTitle": "Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients",
    "officialTitle": "HER2 Retrospective Epidemiology Study Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (HER2 PATH)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, HER2",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 3136,
    "primaryOutcomeMeasure": "The Prevalence of different HER2 expression levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPatients fulfilling all of the following criteria will be eligible for this study:\n\n* Male and female patients must have a histological confirmed diagnosis of BC\n* The patients must be \u226518 years old at the diagnosis.\n* In PART 1, all patients should be diagnosed at FUSCC between Jan 2015 and Dec 2015.\n* In PART 2, all patients should be diagnosed at all participating sites between July 2021 and July 2022.\n* Provision of at least 1 archived HER2 IHC slides associated with confirmed diagnosis of BC, which are in good condition for rescoring.\n* FISH result is available for HER2 IHC2+ in primary scoring.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be disqualified from entering the study:\n\n* Absence of all demographic, histopathologic, clinicopathologic information .\n* Have a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}